Barclays Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $41

Barclays analyst Carter Gould maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of 57.7%

Moomoo News04:31 ET · Ratings

Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Cuts Target Price to $37

Morgan Stanley analyst Terence Flynn maintains $Bristol-Myers Squibb(BMY.US)$ with a sell rating, and adjusts the target price from $40 to $37.According to TipRanks data, the analyst has a success

Moomoo NewsJul 11 09:34 ET · Ratings

Morgan Stanley Sticks to Its Sell Rating for Bristol-Myers Squibb (BMY)

TipRanksJul 11 08:46 ET

Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating

Bristol-Myers Squibb (BMY) has an average hold rating and a price target range of $37 to $75, according to analysts polled by Capital IQ.Price: 41.08, Change: -0.04, Percent Change: -0.10

MT NewswiresJul 11 07:33 ET

Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know

Simply Wall StJul 11 06:15 ET

Bristol-Myers Squibb Company (NYSE:BMY) Is a Favorite Amongst Institutional Investors Who Own 78%

Yahoo FinanceJul 11 05:21 ET